03.07.2024 | Journal Club | Gastroenterologie | Ausgabe: 2024–2
Open Access
Advancing treatment frontiers: elafibranor and seladelpar in the management of primary biliary cholangitis
Zeitschrift: Schweizer Gastroenterologie > Ausgabe: 2024–2
Autoren: Dr. med. Dr. phil. nat. Yakir Guri, Prof. Dr. med. Andreas E. Kremer, PhD, MHBA
Zusammenfassung
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive destruction of the small intrahepatic bile ducts, leading to cholestasis, persistent inflammation, and eventual development of liver fibrosis and cirrhosis. PBC predominantly affects middle-aged women, with a global variation in prevalence and incidence suggesting that both genetic and environmental factors might contribute to its etiology.Über diesen Artikel
Titel: Advancing treatment frontiers: elafibranor and seladelpar in the management of primary biliary cholangitis
Publikationsdatum: 03.07.2024
Verlag: Springer Vienna
Autor*innen: Dr. med. Dr. phil. nat. Yakir Guri, Prof. Dr. med. Andreas E. Kremer, PhD, MHBA
DOI: https://doi.org/10.1007/s43472-024-00132-x
Zeitschrift: Schweizer Gastroenterologie / Gastroentérologie suisse – Gastroenterologia svizzera
Veröffentlicht in: Ausgabe: 2024–2
Print ISSN: 2662–7140
Elektronische ISSN: 2662–7159